BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36031743)

  • 1. CD47 (don't eat me signal) expression levels and its relationship with clinicopathologic features in early-stage prostate carcinoma.
    Semiz HS; Küçük Ü; Kısa E; Keskinkılıç M; Süyün DE; Arayıcı ME; Atağ E; Karaoglu A
    Prostate; 2022 Dec; 82(16):1564-1571. PubMed ID: 36031743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 3. B7-H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy.
    Chen S; Zhan S; Ding S; Zhang Q; Xuan H; Zhang X; Cao L
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16609-16621. PubMed ID: 37715830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment.
    Sakakura K; Takahashi H; Kaira K; Toyoda M; Murata T; Ohnishi H; Oyama T; Chikamatsu K
    Lab Invest; 2016 Sep; 96(9):994-1003. PubMed ID: 27322955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer.
    Wang Q; Feng C; Chen Y; Peng T; Li Y; Wu K; Pu X; Chen H; Liu J
    J Immunol Res; 2023; 2023():2473075. PubMed ID: 37719086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
    Tong B; Wang M
    Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD47 and CD68 expression in breast cancer is associated with tumor-infiltrating lymphocytes, blood vessel invasion, detection mode, and prognosis.
    Chen Y; Klingen TA; Aas H; Wik E; Akslen LA
    J Pathol Clin Res; 2023 May; 9(3):151-164. PubMed ID: 36598153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of CD47 and CD68 expression predicts survival in eastern-Asian patients with non-small cell lung cancer.
    Fu F; Zhang Y; Gao Z; Zhao Y; Wen Z; Han H; Li Y; Hu H; Chen H
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):739-747. PubMed ID: 33392661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle-Mediated CD47-SIRPα Blockade and Calreticulin Exposure for Improved Cancer Chemo-Immunotherapy.
    Luo JQ; Liu R; Chen FM; Zhang JY; Zheng SJ; Shao D; Du JZ
    ACS Nano; 2023 May; 17(10):8966-8979. PubMed ID: 37133900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy.
    Wang H; Sun Y; Zhou X; Chen C; Jiao L; Li W; Gou S; Li Y; Du J; Chen G; Zhai W; Wu Y; Qi Y; Gao Y
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic role of the innate immune signature CD163 and "eat me" signal calreticulin in clear cell renal cell carcinoma.
    Anno T; Tanaka N; Takamatsu K; Hakozaki K; Kufukihara R; Baba Y; Takeda T; Matsumoto K; Morita S; Kosaka T; Mikami S; Nishihara H; Mizuno R; Oya M
    Cancer Immunol Immunother; 2023 Jun; 72(6):1779-1788. PubMed ID: 36646952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the regulation of "Don't Eat-Me" signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy.
    Karizak AZ; Salmasi Z; Gheibihayat SM; Asadi M; Ghasemi Y; Tajbakhsh A; Savardashtaki A
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):511-529. PubMed ID: 36342520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression profiles of CD47 in the tumor microenvironment of salivary gland cancers: a next step in histology-driven immunotherapy.
    Votava M; Bartolini R; Capkova L; Smetanova J; Jiri V; Kuchar M; Kalfert D; Plzak J; Bartunkova J; Strizova Z
    BMC Cancer; 2022 Sep; 22(1):1021. PubMed ID: 36171566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An immunohistochemical evaluation of tumor-associated macrophages (M1 and M2) in carcinoma prostate - An institutional study.
    Hadimani SM; Das S; Harish KG
    J Cancer Res Ther; 2023 Apr; 19(Supplement):S300-S305. PubMed ID: 37148007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of miR-340 controls pancreatic cancer cell
    Xi Q; Zhang J; Yang G; Zhang L; Chen Y; Wang C; Zhang Z; Guo X; Zhao J; Xue Z; Li Y; Zhang Q; Da Y; Liu L; Yao Z; Zhang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
    Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
    J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and Prognostic Significance of CD47-SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer.
    Sugimura-Nagata A; Koshino A; Inoue S; Matsuo-Nagano A; Komura M; Riku M; Ito H; Inoko A; Murakami H; Ebi M; Ogasawara N; Tsuzuki T; Takahashi S; Kasugai K; Kasai K; Inaguma S
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33799989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD47-targeted immunotherapy unleashes antitumour immunity in Epstein-Barr virus-associated gastric cancer.
    Duan Y; Li S; Huang B; Dou Y; Kong P; Kang W; Xu D
    Clin Immunol; 2023 Feb; 247():109238. PubMed ID: 36690192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
    Wang X; Wang Y; Hu J; Xu H
    Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.